First-in-human Study of 7MW4911 in GI Cancer

This first-in-human study is testing a new drug called 7MW4911 in people with advanced gastrointestinal (GI) cancers (such as stomach, colorectal, esophageal, or other GI cancers) whose cancer has progressed after standard treatments. **You may be eligible if...** - You are 18 or older and have advanced or metastatic gastrointestinal cancer - Your cancer has progressed after receiving standard-of-care treatment - You have at least one measurable tumor on scans - You have adequate blood, liver, and kidney function - You are reasonably functional (ECOG 0–1) with at least 3 months life expectancy **You may NOT be eligible if...** - You have active, untreated brain metastases - You have an active autoimmune disease (except well-controlled conditions like type 1 diabetes or hypothyroidism) - You have active HIV, hepatitis B, or hepatitis C infection - You have had a bone marrow or organ transplant - You have significant uncontrolled heart disease - You have poorly controlled blood sugar - You are pregnant or breastfeeding - You have had prior treatment with a similar drug (CDH17-targeting therapy) or a topoisomerase I payload antibody-drug conjugate Talk to your doctor to see if this trial is right for you.